Franklin Chen, MD
Hematology · Winston Salem, NCNPI 1992979736
Payments from drug & device makers
Across 518 payments — averaging $2586.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$438K
- EMD Serono, Inc.$186K
- Genentech, Inc.$186K
- E.r. Squibb & Sons, L.L.C.$129K
- Sanofi US Services Inc.$79K
- AbbVie$71K
- plus $251K from 31 others
What the payments were for
- Consulting fees$23,9728%
- Speaking & faculty fees$261,92285%
- Travel & lodging$10,9374%
- Food & beverage$9,9923%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 81 | $438,184 |
| EMD Serono, Inc. | 26 | $186,411 |
| Genentech, Inc. | 14 | $186,162 |
| E.r. Squibb & Sons, L.L.C. | 48 | $128,861 |
| Sanofi US Services Inc. | 17 | $78,741 |
| AbbVie | 50 | $70,787 |
| Johnson & Johnson | 62 | $52,313 |
| Sanofi | 38 | $47,852 |
| GSK | 35 | $45,079 |
| Amgen | 48 | $40,076 |
| Astrazeneca UK Limited | 10 | $40,030 |
| Karyopharm Therapeutics Inc. | 16 | $8,828 |
| Ares Trading SA | 5 | $4,000 |
| AstraZeneca | 11 | $2,622 |
| Janssen Scientific Affairs, LLC | 4 | $2,166 |
| Bristol Myers Squibb | 5 | $1,833 |
| Genentech USA, Inc. | 6 | $1,714 |
| Seagen Inc. | 1 | $1,375 |
| Bayer | 1 | $950 |
| Pfizer | 7 | $343 |
| Sobi, Inc | 4 | $254 |
| ADC Therapeutics America, Inc. | 2 | $246 |
| Gilead(2 entities) | 4 | $167 |
| Incyte Corporation | 3 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Beone Medicines USA, Inc. | 4 | $97 |
| Adaptive Biotechnologies Corporation | 2 | $58 |
| Legend Biotech USA Inc. | 1 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Cycle Pharmaceuticals Inc | 2 | $46 |
| Astellas Pharma US Inc | 2 | $42 |
| Novartis | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Tempus AI, Inc | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,339,769 in reported general payments places this provider in the 75th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 121 | $1,656,629 |
| JakafiRuxolitinib Phosphate | 62 | $1,011,501 |
| CalquenceAcalabrutinib Maleate | 59 | $857,314 |
| ImbruvicaIbrutinib | 35 | $557,179 |
| VenclextaVenetoclax | 50 | $533,155 |
| PomalystPomalidomide | 24 | $520,195 |
| NinlaroIxazomib Citrate | 13 | $173,147 |
| EliquisApixaban | 45 | $40,016 |
| XareltoRivaroxaban | 19 | $11,894 |
| ValacyclovirValacyclovir Hcl | 87 | $4,173 |
| CholestyramineCholestyramine (With Sugar) | 13 | $2,000 |
| Hydroxyurea | 68 | $1,822 |
| Dexamethasone | 59 | $1,235 |
| Oxycodone Hcl | 55 | $887 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,833 | $1,656,629121 claims |
| Incyte CorporationJakafi | $163 | $1,011,50162 claims |
| AstraZenecaCalquence | $2,622 | $857,31459 claims |
| AbbVieVenclexta | $70,787 | $533,15550 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $128,861 | $520,19524 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $125 | $173,14713 claims |
| PfizerEliquis | $343 | $40,01645 claims |
| Johnson & JohnsonXarelto | $52,313 | $11,89419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 hematology providers in North Carolina.
Other hematology in Winston Salem
- James DuganWinston Salem$3.7M
- Konstantinos LontosWinston Salem$467K
- Jan MorebWinston Salem$113K
- John OwenWinston Salem$7K
- Kathleen ElliottWinston Salem$7K
- Alan Zausner SkarbnikCharlotte$9.8M
- Ryan JacobsCharlotte$8.5M
- Sascha TuchmanDurham$6.8M
- Manisha BhutaniCharlotte$6.8M
- Peter VoorheesCharlotte$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.